Search the Newsreel

Diodes Inc (DIOD) director Evan Yu reports direct ownership of 12,000 shares

Diodes Incorporated (DIOD) director Evan Yu has filed an initial statement of beneficial ownership (Form 3), reporting direct ownership of 12,000 shares of the company's common stock. This filing establishes his equity position as an insider. The report clarifies that Yu is a director …

Solidion Technology Q2 Revenue Reaches $124914 After $35 Million Private Placement

Solidion Technology reported Q2 revenue of $124,914. This revenue figure follows a significant $35 million private placement. The article details the company's financial performance in the second quarter.

AudioEye expects over $15M run rate adjusted EBITDA by end of 2026 as it raises full-year adjusted EBITDA guidance to at least $12.7M

Earnings Call Insights: AudioEye (AEYE) Q2 2026 MANAGEMENT VIEW * “Q2 marked our 42nd consecutive quarter of sequential revenue growth,” and the company reported revenue of $10.7 million and ARR of $42.3 million, with CEO Kelly Georgevich stating that the quarter “reflects low double-digit …

Diodes Inc (DIOD) Stock Down 9.2% but Still Overvalued -- GF Score: 80/100

Diodes Inc (DIOD) shares dropped 9.2% to $97.19, yet GuruFocus assesses the stock as significantly overvalued by 37.8% compared to its GF Value of $70.54. Despite a strong GF Score of 80/100, reflecting robust financial health and momentum, its low valuation rank of 3/10 …

Diodes (DIOD) director Evan Yu receives 2,250 restricted stock units vesting from 2027

Diodes Incorporated director Evan Yu was awarded 2,250 restricted stock units (RSUs) on August 12, 2026, at no cash cost, under a Rule 16b-3 Plan. These RSUs will vest in four equal installments starting May 26, 2027. Following this grant, Yu's direct ownership in …

Audioeye Q2 Earnings Call Highlights

Key Points Interested in Audioeye, Inc.? Here are five stocks we like better. Revenue and recurring growth continued: AudioEye's second-quarter revenue rose 9% year over year to $10.7 million, while ARR increased 11% to $42.3 million, extending its sequential revenue-growth streak to 42 quarters. …

Earnings call transcript: AudioEye posts Q2 2026 revenue beat, shares rise 2.2%

AudioEye reported mixed Q2 2026 results, with revenue of $10.71 million slightly exceeding estimates, while adjusted earnings missed forecasts, resulting in a net loss of $0.07 per share. Despite the earnings miss, shares rose 2.2% in after-hours trading as investors focused on improving margins, …

AudioEye (AEYE) Q2 Earnings and Revenues Beat Estimates

AudioEye (AEYE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Audioeye (NASDAQ:AEYE) Releases Earnings Results, Beats Estimates By $0.02 EPS

AudioEye (NASDAQ:AEYE) reported its quarterly earnings, beating analyst estimates by $0.02 EPS with $0.23 against a $0.21 consensus. The company also exceeded revenue expectations, reporting $10.72 million against an estimated $10.69 million. Despite flat share prices, AudioEye updated its fiscal 2026 EPS guidance to …

Audioeye (NASDAQ:AEYE) Issues FY 2026 Earnings Guidance

AudioEye (NASDAQ:AEYE) has issued updated FY 2026 earnings guidance, projecting EPS of $0.98, surpassing the $0.85 consensus, and revenue between $43.5 million and $44.0 million, aligning with the $43.9 million consensus. The company also set Q3 2026 EPS guidance at $0.26–$0.28, following a slight …

AudioEye: Q2 Earnings Snapshot

AudioEye Non-GAAP EPS of $0.23 beats by $0.02, revenue of $10.7M in-line

* AudioEye press release [https://seekingalpha.com/pr/20619034-audioeye-reports-record-second-quarter-2026-results] (AEYE [https://seekingalpha.com/symbol/AEYE]): Q2 Non-GAAP EPS of $0.23 beats by $0.02. * Revenue of $10.7M (+8.1% Y/Y) in-line. * Annual Recurring Revenue ("ARR") as of June 30, 2026, increased sequentially to $42.3M from $41.2M as of March 31, 2026, and …

AudioEye Reports Record Second Quarter 2026 Results

AudioEye, Inc. announced record financial results for the second quarter ended June 30, 2026, marking its forty-second consecutive period of revenue growth with 11% year-over-year ARR growth. The company reported a record $3.0M in Adjusted EBITDA and increased its full-year Adjusted EBITDA guidance, expecting …

VRTS Looks 10.5% Undervalued on GF Value™ Despite Cash-Flow Chal

Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Cardiol Therapeutics (NASDAQ:CRDL) recently announced its quarterly earnings, reporting an EPS of ($0.04), which surpassed analyst expectations of ($0.09) by $0.05. Following the announcement, the company's shares increased by 1.3% to $1.52, with a market capitalization of approximately $176.15 million. Analyst sentiment for CRDL …

Cardiol Therapeutics GAAP EPS of -C$0.05

* Cardiol Therapeutics press release [https://seekingalpha.com/filing/309942772] (CRDL:CA [https://seekingalpha.com/symbol/CRDL:CA]): Q2 GAAP EPS of -C$0.05. MORE ON CARDIOL THERAPEUTICS * Historical earnings data for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/earnings] * Financial information for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/income-statement]

Radiopharm Theranostics (RADX) seeks shareholder approval for placements, SPP and new warrants

Radiopharm Theranostics (RADX) is seeking shareholder approval for a multi-component capital raise, including placements, a share purchase plan (SPP), and various options and warrants, at a virtual extraordinary general meeting on September 11, 2026. The company is asking shareholders to ratify previously issued shares …

Studio City International Holdings Limited Announces Unaudited Second Quarter 2026 Earnings

Studio City MACAU, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Studio City International Holdings Limited (NYSE: MSC) ("Studio City" or the "Company"), a world-class integrated resort located in Cotai, Macau, today reported its unaudited financial results for the second quarter of 2026. Total operating revenues …

Studio City Reports $15.6M Q2 Net Loss as Revenue Falls

Studio City International Holdings (NYSE: MSC) reported a Q2 2026 net loss of $15.6 million, widening from $3.7 million a year prior, as operating revenues declined to $164.6 million from $190.1 million. This decrease was primarily attributed to softer mass market table games performance …

Radiopharm Theranostics Calls Virtual Extraordinary General Meeting for September 2026

Diodes Incorporated Announces Proposed Private Placement of $325 Million of Convertible Senior Notes

PLANO, Texas, August 13, 2026--(BUSINESS WIRE)--Diodes Incorporated ("Diodes") (Nasdaq: DIOD), today announced it intends to offer, subject to market conditions and other factors, $325 million aggregate principal amount of Convertible Senior Notes due 2031 (the "notes") in a private placement (the "offering") only to …

Lionsgate Studios Corp. (NYSE:LION) Receives Average Recommendation of "Moderate Buy" from Analysts

Lionsgate Studios Corp. (NYSE:LION) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $15.575, exceeding its current share price of $11.73. Recent analyst actions include downgrades to "neutral" by Citigroup and Zacks Research, while Barrington Research and …

Lionsgate Studios (LION) Faces Public Pressure To Recast Its Business For AI

5 Revealing Analyst Questions From Ingredion’s Q2 Earnings Call

5 Revealing Analyst Questions From Ingredion's Q2 Earnings Call Ingredion's Q2 results were met favorably by the market, driven by ongoing momentum in its Texture & Healthful Solutions segment. Management highlighted nine consecutive quarters of volume growth in this area, supported by customer demand …

Angel Studios Inc (ANGX) (Q2 2026) Earnings Call Highlights: Guild Membership Surges 99% as ...

Is Diodes Inc (DIOD) Overvalued After 3.8% Rally? GF Value Says

Diodes Inc (DIOD) recently saw its shares rally by 3.8% to $107.04, but GuruFocus's GF Value suggests the stock is significantly overvalued by 58.7%, with an estimated intrinsic value of $67.44. The company has a strong financial strength rating of 9/10 but a weak …

Radiopharm Theranostics Calls Extraordinary General Meeting to Ratify Placement Shares and Approve Capital Raising

Radiopharm Theranostics Limited (ASX:RAD) has announced an Extraordinary General Meeting (EGM) for September 11, 2026, to seek shareholder approval for various share issuances and capital raising activities. Shareholders will vote on ratifying previously issued placement shares and ADS shares, and approving the issuance of …

Radiopharm Theranostics Announces Virtual EGM on September 11, 2026 to Approve Share Issuances and Capital Raise

Radiopharm Theranostics Limited (ASX:RAD) has scheduled a virtual Extraordinary General Meeting (EGM) for September 11, 2026, to seek shareholder approval for various share issuances and capital raising initiatives. Shareholders will vote on ratifying previously issued shares, approving new placements to sophisticated investors, and endorsing …

Diodes (DIOD) Q2 2026 Earnings Call Transcript

Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027

Solidion Technology (STI) widens Q2 2026 loss despite sales jump and lower expenses

Solidion Technology (STI) reported a wider net loss of $2,886,756 for Q2 2026, compared to $2,113,859 in the prior year, despite a significant increase in net sales to $124,914 and lower operating expenses. The increased loss was primarily driven by higher "other expenses," including …

Form 8K Solidion Technology Inc For: 12 August By Investing.com

This article announces the filing of a Form 8K by Solidion Technology Inc. on August 12. It reiterates this information and includes the company's stock symbol STI and its current price performance.

Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

What’s Next For Cardiol Therapeutics (TSX:CRDL) Research?

Cardiol Therapeutics (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies for cardiovascular conditions, with its research strategy centered on addressing unmet therapeutic needs in this area. The company's future hinges on clinical execution, regulatory developments, and the quality of its trial …

Medios steigert Umsatz im ersten Halbjahr 2026 auf über 1 Milliarde Euro, senkt aber die Gewinnprognose

Diodes Incorporated (NASDAQ: DIOD) posts 22% Q2 revenue growth and strong Q3 outlook